NCT07374588Completed
Impact of Medication Education on Adherence and Side Effects
The Effect of Medication Education on Treatment Adherence and Side Effects in Psychiatric Inpatients: An Intervention Study
Source: ClinicalTrials.gov · Last updated 24 Aug 2026
Brief summary (registry, in English)
Severe mental disorders such as schizophrenia, bipolar disorder, and psychotic depression often require long-term or lifelong medication treatment. However, many psychiatric patients have difficulty adhering to their prescribed medication regimens due to factors such as lack of information, fear of side effects, and negative experiences with psychotropic medications. Poor treatment adherence is associated with symptom relapse, prolonged hospitalization, increased rehospitalization rates, reduced quality of life, and higher health care costs. Medication education is a key psychosocial intervention aimed at improving patients' understanding of their illness, treatment process, and potential medication side effects. Providing structured medication education may enhance treatment adherence and help patients recognize and manage side effects more effectively. This intervention study aims to evaluate the effect of a structured medication education program on treatment adherence and medication-related side effects among psychotic inpatients hospitalized in a psychiatric clinic, including patients diagnosed with schizophrenia, schizoaffective disorder, schizophreniform disorder, bipolar disorder with psychotic features, and major depressive disorder with psychotic features. The findings of this study are expected to contribute to the development of effective psychosocial interventions to improve medication adherence and treatment outcomes in psychiatric inpatient settings.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 64 (actual)
- First submitted
- 10 Jan 2026
- Start date
- 30 Jan 2026
- Primary completion date
- 15 Jun 2026
- Lead sponsor
- Cumhuriyet University
- Diseases
- Schizophrenia, Depression, Bipolar disorder
- NCT number
- NCT07374588
What you commit to
- Study type: Interventional
- Participants enrolled: 64
- From 30 Jan 2026 to the primary completion date, 15 Jun 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Presence of severe cognitive impairment or intellectual disability
- Acute medical or neurological conditions that may interfere with participation
Other
- Severe agitation or acute psychotic symptoms preventing participation
- Hearing or communication impairments that limit participation in educational sessions
- Participation in another psychosocial intervention study during the study period
Who the study is looking for
- Adults aged 18-65 years
- Hospitalized in a psychiatric inpatient clinic
- Diagnosed with schizophrenia, schizoaffective disorder, schizophreniform disorder, bipolar disorder with psychotic features, or major depressive disorder with psychotic features
- Receiving psychotropic medication treatment
- Clinically stable and able to participate in educational sessions
- Able to communicate verbally and understand the content of the education
- Provided written informed consent
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sivas Cumhuriyet Univesity Hospital Coordinator of this site? Confirm its status | Sivas | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.